Trump revives pharma tariffs with 100% charges, but leaves loopholes
BioPharma Dive
Section 232 national security levies won't apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.
pharminent
April 3, 2026 (Last updated: April 3, 2026)
BioPharma Dive
Section 232 national security levies won’t apply to a wide array of drugs, meaning the overall threat to the sector should be low, according to one analyst.
